These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
348 related articles for article (PubMed ID: 23384436)
1. Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: a retrospective cohort study. Takeuchi Y; Fujino Y; Watanabe M; Takahashi M; Nakagawa T; Takeuchi A; Bonkobara M; Kobayashi T; Ohno K; Uchida K; Asano K; Nishimura R; Nakayama H; Sugano S; Ohashi Y; Tsujimoto H Vet J; 2013 Jun; 196(3):492-8. PubMed ID: 23384436 [TBL] [Abstract][Full Text] [Related]
2. Prevalence of exon 11 internal tandem duplications in the C-KIT proto-oncogene in Australian canine mast cell tumours. Tamlin VS; Kessell AE; Mccoy RJ; Dobson EC; Smith TS; Hebart M; Brown L; Mitrovic D; Peaston AE Aust Vet J; 2017 Oct; 95(10):386-391. PubMed ID: 28948627 [TBL] [Abstract][Full Text] [Related]
3. Comparison of 2- and 3-category histologic grading systems for predicting the presence of metastasis at the time of initial evaluation in dogs with cutaneous mast cell tumors: 386 cases (2009-2014). Stefanello D; Buracco P; Sabattini S; Finotello R; Giudice C; Grieco V; Iussich S; Tursi M; Scase T; Di Palma S; Bettini G; Ferrari R; Martano M; Gattino F; Marrington M; Mazzola M; Elisabetta Vasconi M; Annoni M; Marconato L J Am Vet Med Assoc; 2015 Apr; 246(7):765-9. PubMed ID: 25794126 [TBL] [Abstract][Full Text] [Related]
4. Expression of Ki67, BCL-2, and COX-2 in canine cutaneous mast cell tumors: association with grading and prognosis. Vascellari M; Giantin M; Capello K; Carminato A; Morello EM; Vercelli A; Granato A; Buracco P; Dacasto M; Mutinelli F Vet Pathol; 2013 Jan; 50(1):110-21. PubMed ID: 22673539 [TBL] [Abstract][Full Text] [Related]
5. Histologic grading of canine mast cell tumor: is 2 better than 3? Sabattini S; Scarpa F; Berlato D; Bettini G Vet Pathol; 2015 Jan; 52(1):70-3. PubMed ID: 24513799 [TBL] [Abstract][Full Text] [Related]
6. In situ c-KIT mRNA quantification of canine cutaneous mast cell tumours and its relationship to prognostic factors. Seung BJ; Cho SH; Kim SH; Bae MK; Lim HY; Sur JH Vet Comp Oncol; 2021 Mar; 19(1):132-139. PubMed ID: 32926564 [TBL] [Abstract][Full Text] [Related]
7. HSP32 and HSP90 Immunoexpression, in Relation to Kit Pattern, Grading, and Mitotic Count in Canine Cutaneous Mast Cell Tumors. Romanucci M; Massimini M; Ciccarelli A; Malatesta D; Bongiovanni L; Gasbarre A; Della Salda L Vet Pathol; 2017 Mar; 54(2):222-225. PubMed ID: 27627984 [TBL] [Abstract][Full Text] [Related]
8. All subunits of the interleukin-2 receptor are expressed by canine cutaneous mast cell tumours. Meyer A; Gruber AD; Klopfleisch R J Comp Pathol; 2013 Jul; 149(1):19-29. PubMed ID: 23276382 [TBL] [Abstract][Full Text] [Related]
9. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors. Kiupel M; Webster JD; Kaneene JB; Miller R; Yuzbasiyan-Gurkan V Vet Pathol; 2004 Jul; 41(4):371-7. PubMed ID: 15232137 [TBL] [Abstract][Full Text] [Related]
10. The value of molecular expression of KIT and KIT ligand analysed using real-time polymerase chain reaction and immunohistochemistry as a prognostic indicator for canine cutaneous mast cell tumours. Costa Casagrande TA; de Oliveira Barros LM; Fukumasu H; Cogliati B; Chaible LM; Dagli ML; Matera JM Vet Comp Oncol; 2015 Mar; 13(1):1-10. PubMed ID: 23294979 [TBL] [Abstract][Full Text] [Related]
11. Canine subcutaneous mast cell tumors: cellular proliferation and KIT expression as prognostic indices. Thompson JJ; Yager JA; Best SJ; Pearl DL; Coomber BL; Torres RN; Kiupel M; Foster RA Vet Pathol; 2011 Jan; 48(1):169-81. PubMed ID: 21160022 [TBL] [Abstract][Full Text] [Related]
12. Canine mast cell tumours part I: Clinical and survival outcomes. Tamlin VS; Bottema CDK; Woolford L; Dobson EC; Kessell AE; Peaston AE Vet Med Sci; 2022 Jul; 8(4):1409-1420. PubMed ID: 35505524 [TBL] [Abstract][Full Text] [Related]
13. Epidemiological assessment of the risk of canine mast cell tumours based on the Kiupel two-grade malignancy classification. Śmiech A; Ślaska B; Łopuszyński W; Jasik A; Bochyńska D; Dąbrowski R Acta Vet Scand; 2018 Nov; 60(1):70. PubMed ID: 30390687 [TBL] [Abstract][Full Text] [Related]
14. Tandem duplication of KIT exon 11 influences the proteome of canine mast cell tumours. Schlieben P; Meyer A; Weise C; Bondzio A; Gruber AD; Klopfleisch R J Comp Pathol; 2013 May; 148(4):318-22. PubMed ID: 22935087 [TBL] [Abstract][Full Text] [Related]
15. Mutation and methylation status of KIT and TP Vozdova M; Kubickova S; Fictum P; Cernohorska H; Fröhlich J; Rubes J Vet Comp Oncol; 2020 Sep; 18(3):438-444. PubMed ID: 31574575 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of prognostic indicators in dogs with multiple, simultaneously occurring cutaneous mast cell tumours: 63 cases. O'Connell K; Thomson M Vet Comp Oncol; 2013 Mar; 11(1):51-62. PubMed ID: 22235766 [TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical and Molecular Genetic Analysis of Canine Digital Mast Cell Tumours. Conrad D; Kehl A; Müller T; Klopfleisch R; Aupperle-Lellbach H Animals (Basel); 2023 May; 13(10):. PubMed ID: 37238124 [TBL] [Abstract][Full Text] [Related]
18. Histopathological features of subcutaneous and cutaneous mast cell tumors in dogs. Minnoye S; De Vos S; Beck S; Duchateau L; Hubers M; David S; Fortrie R; de Rooster H Acta Vet Scand; 2024 Oct; 66(1):53. PubMed ID: 39354622 [TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of internal tandem duplications in the c-kit of dogs with multiple mast cell tumours. Amagai Y; Tanaka A; Matsuda A; Jung K; Oida K; Nishikawa S; Jang H; Matsuda H J Small Anim Pract; 2013 Jul; 54(7):377-80. PubMed ID: 23614673 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors. Webster JD; Kiupel M; Yuzbasiyan-Gurkan V BMC Cancer; 2006 Apr; 6():85. PubMed ID: 16579858 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]